Aerpio AKB-9778-Cl-5001

Status: Enrolling

ClinicalTrials.gov Identifier: NCT03197870

Aerpio: Phase 2 Double-Masked, Placebo-controlled Study to Assess the Safety and Efficacy of Subcutaneously Administered AKB-9778 15 MG Once Daily or 15 MG Twice Daily for 12 Months in Patients with Moderate to Severe Non-Proliferative Diabetic Retinopathy.

Condition: Non-Proliferative Diabetic Retinopathy

Study Type: Interventional

Duration: 12 months

Eligibility:

  • Adults: 18 through 80 years of age
  • Sexes: All
  • Accepts Healthy Volunteers: No

For additional information, please click here

Go Back
This entry was posted in Uncategorized. Bookmark the permalink.